RPG Life Sciences: Subsidiary merger scheme approved by board

Scheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹3055.00

prior close

₹3055.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%-0.4% vs market

Pharmaceuticals peers, median of 172sector-1.5%-0.5% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.8

15m

+0.3

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-1.6-0.4-1.5-0.5

Next day

+1.6-0.6+2.2-1.0+2.6

-0.4-0.8+0.4-1.9+1.5

-3.4-2.1-1.3-2.4-1.0

-4.9-2.1-2.8-3.2-1.7

-4.2-0.8-3.4-2.4-1.9

-7.4-3.8-3.6-4.2-3.1

15d

-8.0-6.9-1.1-7.8-0.1

-6.6-8.0+1.4-6.4-0.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Subsidiary RPG Active Pharma Limited (RPGAP) board approved merging its wholly owned subsidiary Actis Generics into RPGAP. Actis Generics has net worth of INR 34.60 Cr and FY26 revenue of INR 45.96 Cr. RPGAP net worth is INR 34.75 Cr. Since Actis is wholly owned, no new shares will be issued and its shares will be cancelled. No change in RPG Life Sciences shareholding pattern. Scheme needs NCLT and shareholder approvals.

Likely market impact

Internal restructuring with no share dilution or change in shareholding pattern. Subject to NCLT approval. Aims to streamline operations and cut costs.